Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress

Stock Track

02-28

AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.

The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.

AbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.

Other key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1157205544"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157205544\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1157205544?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157205544","market":"hk","top_or_hot":-1,"title":"Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress","media":"Stock Track","content":"<p>AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.</p>\n\n<p>The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.</p>\n\n<p>AbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.</p>\n\n<p>Other key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-28 22:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.</p>\n\n<p>The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.</p>\n\n<p>AbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.</p>\n\n<p>Other key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1157205544","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157205544","pubTimestamp":1740753761,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AbCellera Biologics  stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.AbCellera announced that its two lead antibody","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"尽管管道取得进展，AbCellera股价在2024年跌幅扩大后盘前暴跌16.78%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.\nThe biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.\nAbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.\nOther key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}